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Turner et al. [1] raise an important and timely issue about the
management of CF patients suffering chronic infection with
methicillin-resistant Staphylococcus aureus (MRSA), given
that the prevalence of MRSA in respiratory cultures of CF
patients has increased over the past decade. In our study [2], the
prevalence of chronic MRSA colonization in the CF Center of
the University Hospital of Brussels was 12.6%. Our spirometric
data showed that a MRSA episode entailed an FEV1 decline
that was almost double that predicted for CF patients who could
remain unaffected by MRSA. These results prompted us to
support the need for a more pro-active policy of MRSA
management of CF patients which might include enhanced
segregation, infection control and eradication. While segrega-
tion avoids cross-infections, we acknowledge that it also
provokes social isolation of a CF patient, who is already
burdened by a complicated and time-consuming CF manage-
ment schedule.
Upon examination of the follow-up period in the cohort used
for our study [2], we identified three patients (i.e., 15%) who
cleared MRSA without eradication treatment. Interestingly, two
of these three patients had a negative screening swab of the
nose; this could provide a clue to define a subgroup which can
become free of MRSA even after a certain period of recurrent
positive cultures for MRSA. Given the limited number of such
patients reported by Turner et al. [1] or by us, generalization of
these results should be handled with caution. To fully delineate
the impact of MRSA colonization larger prospective longitudinal
studies are needed, preferably complemented by molecular
characterization of MRSA including differentiation between
more aggressive strain carrying virulence factors such as PVL
[3]. Propelled by the urgent need for more convincing data about
aggressive MRSA treatment, MRSA patient segregation and
MRSA screening, we are now performing a multi-centre
prospective study, linking molecular types to clinical outcomes.
We would like to identify strains of MRSA which are more1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.08.002virulent and should be isolated and also identify subgroups of
patients which can benefit most from eradication of MRSA.References
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